Hyderabad-based manufacturer of Active Pharmaceutical Ingredients (APIs) and pharmaceutical intermediates, WHO-GMP certified with EU Written Confirmation for select APIs.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 13 | 13 | 13 | 18 | 23 | 23 | 24 | 24 |
| Reserves | 23 | 27 | 31 | 62 | 148 | 164 | 189 | 198 |
| Borrowings | 5 | 7 | 10 | 1 | 6 | 10 | 88 | 79 |
| Other Liabilities | 16 | 12 | 14 | 51 | 54 | 59 | 55 | 47 |
| Total Liabilities | 57 | 59 | 68 | 132 | 230 | 256 | 357 | 349 |
| AssetsFixed Assets | 15 | 14 | 14 | 74 | 56 | 60 | 76 | 61 |
| CWIP | 0 | 0 | 0 | 0 | 2 | 5 | 0 | 13 |
| Investments | 7 | 7 | 7 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 35 | 38 | 48 | 59 | 172 | 191 | 281 | 275 |
| Total Assets | 57 | 59 | 68 | 132 | 230 | 256 | 357 | 349 |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 2 | -2 | -1 | 12 | 24 | -47 | -11 | -64 |
| Cash from Investing | -1 | 0 | 0 | -2 | -38 | 19 | 1 | -5 |
| Cash from Financing | 1 | 0 | 2 | -2 | 21 | 74 | 5 | 65 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 1 | -2 | -2 | 10 | -16 | -31 | -20 | -76 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (19.3×) and current (13.5×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 62.2% growth and a 13× exit, ₹11 only delivers your return if you pay ₹61. The price is currently baking in 18% growth.
EPS grows 62.2%/yr for 5 years, then fades to 6% over 2, exits at 13×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 62.2% | 1.27 |
| FY28 | 62.2% | 2.05 |
| FY29 | 62.2% | 3.33 |
| FY30 | 62.2% | 5.40 |
| FY31 | 62.2% | 8.76 |
| FY32 | 34.1% ·fade | 11.74 |
| FY33 | 6.0% ·fade | 12.45 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.